Compare Cardinal Health Inc (CAH) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs GE Vernova Inc — how do they compare? Cardinal Health Inc trades at $237.11 (market cap $55.88B), while GE Vernova Inc trades at $1,038.31 (market cap $269.50B). The key difference: GE Vernova Inc is far larger — about 4.8× Cardinal Health Inc's market cap, and Cardinal Health Inc pays the higher dividend (0.86%). Which is the better fit depends on your goals.
| CAH | GEV | |
|---|---|---|
Market Cap | $55.88B | $269.50B |
Sector | Health | Technology |
52-Week High | $240.26 | $1.17K |
52-Week Low | $146.04 | $547.96 |
Enterprise Value | $59.91B | $259.17B |
Dividend Yield | 0.86% | 0.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $236.87, down 0.13% on the day, near its 52-week high. The stock shows strong momentum with four consecutive quarterly EPS beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Technical indicators are bullish overall, with moving averages supporting upward trends. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%.
Outlook remains positive driven by robust pharmaceutical demand and optimistic FY2027 guidance. Key risks include high debt levels and thin profit margins. Analysts maintain a bullish consensus with a $266.43 price target, representing 12.5% upside. The stock presents a growth opportunity but requires monitoring of margin pressures and cash flow volatility.
GE Vernova (GEV) trades at $1,038.13, up 4.77% with strong bullish momentum. The stock shows robust fundamentals with 23% net income margin and 91% ROE, though valuation ratios appear elevated. Recent Q2 2026 earnings missed expectations, but the company maintains a massive $176 billion backlog and benefits from AI-driven power demand. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus remains strongly positive with 76% buy ratings.
Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, but premium valuation and execution risks on backlog conversion warrant caution. The stock offers growth exposure to power grid modernization with upside to the $1,270 consensus target, though investors should monitor quarterly execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
